الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>ABT-670

ABT-670

رقم الكتالوجGC33552

ABT-670 هو ناهض انتقائي متاح حيويًا عن طريق الفم لمستقبلات الدوبامين D4 ، مع EC50 من 89 نانومتر ، 160 نانومتر ، و 93 نانومتر للإنسان D4 ، النمس D4 ، والفأر D4 ، على التوالي

Products are for research use only. Not for human use. We do not sell to patients.

ABT-670 التركيب الكيميائي

Cas No.: 630119-43-6

الحجم السعر المخزون
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire
10mg Please Inquire Please Inquire
20mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ABT-670 is a selective, oral bioavailable agonist of dopamine D4 receptor, with EC50 of 89 nM, 160 nM, and 93 nM for human D4, ferret D4, and rat D4, respectively.

ABT-670 is a selective D4 agonist, with EC50 of 89 nM, 160 nM, and 93 nM for human D4, ferret D4, and rat D4, respectively[1].

ABT-670 (0.1 μmol/kg) robustly induces a high (75%) incidence of erections in male rats. ABT-670 exhibits excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability[1].

[1]. Patel MV, et al. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem. 2006 Dec 14;49(25):7450-65.

مراجعات

Review for ABT-670

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ABT-670

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.